DÄ internationalArchiveReferences

Review article

Congenital and Acquired Polycythemias

Dtsch Arztebl Int 2008; 105(4): 62-8; DOI: 10.3238/arztebl.2008.0062

Siegel, F P; Petrides, P E

1. Gorris L, Hacke D, Ludwig U: Bellas Blut. Der Spiegel 2007; 27: 64.
2. Rives S, Pahl HL, Florensa L et al.: Molecular genetic analyses in familiar and sporadic congenital primary erythrocytosis. Haematologica 2007; 92: 674–7. MEDLINE
3. Gordeuk VR, Prchal JT: Vascular complications in Chuvash polycythemia. Semin Thromb Hemost 2006; 32: 289–94. MEDLINE
4. Thorne SA: Management of polycythaemia in adults with cyanotic congenital heart disease. Heart 1998; 79: 315–6. MEDLINE
5. De Los Santos JF, Thomas GM: Anemia correction in malignancy management: Threat or opportunity? Gyn Onc 2007; 105: 517–29. MEDLINE
6. Petrides PE: Primäre Thrombozythämie: Diagnose und Therapie. Med Klin 2006; 101: 624–34. MEDLINE
7. Wautier MP, El NW, Gane P et al.: Increased adhesion to endothelial cells of erythrocytes from patients with Polycythemia Vera is mediated by laminin-alpha5-chain and Lu/BCAM. Blood 2007; 110: 894–901. MEDLINE
8. Wehmeier A, Sudhoff T, Meierkord F: Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost. 1997; 23: 391–402. MEDLINE
9. Anger B, Haug U, Seidler R, Heimpel H: Polycythemia vera. A clinical study of 141 patients. Blut 1989; 59: 493–500. MEDLINE
10. Siegel F, Petrides PE: Aquagener Pruritus: Diagnose und Therapie. Arzneimitteltherapie 2007, 25: 9–15.
11. Kutti J, Ridell B: Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001; 49: 164–6. MEDLINE
12. Passamonti F, Rumi E, Pungolino E et al.: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755–61. MEDLINE
13. Gangat N, Strand J, Li CY et al.: Leucocytosis in polycythemia vera predicts both inferior survival and leucaemic transformation. Br J Haemat 2007, 138: 354–8. MEDLINE
14. Campbell PJ, Green AR: The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–66. MEDLINE
15. Scott LM, Tong W, Levine RL et al.: JAK2-exon-12-mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–68. MEDLINE
16. Tefferi A: JAK2-mutations in polycythemia vera. Molecular mechanisms and clinical applications. N Engl J Med. 2007; 356: 444–5. MEDLINE
17. Berk PD, Goldberg JD, Silverstein MN et al.: Increased incidence if acute leukemia in Polycythemia Vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-7. MEDLINE
18. Boughton BJ: Chronic myeloproliferative disorders: improved platelet aggregation following venesection. Br J Haematol 1978; 39: 589–98. MEDLINE
19. Landolfi R, Marchioli R, Kutti J et al.: ECLAP (European Collaboration on Low Dose Aspirin in Polycythemia Vera): efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114–24. MEDLINE
20. Spivak J: Daily aspirin-only half the answer. N Engl J Med. 2004; 350: 99–101. MEDLINE
21. McMullin MF: A review of the therapeutic agents used in the management of polycythaemia vera. Hematol Oncol 2007; 25: 58–65. MEDLINE
22. Samuelsson J, Hasselbalch H, Bruserud O et al.: A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life. Cancer 2006; 106: 2397–405. MEDLINE
23. Petrides PE: Anagrelid zur Behandlung der primären Thrombozythämie. Arzneimitteltherapie 2005; 22: 225–35.
24. Streiff MB, Smith B, Spivak JL: The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002; 99: 1144–9. MEDLINE
25. Marchioli R, Finazzi G, Landolfi R et al.: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224–32. MEDLINE